Table 2.
Summary of Recommendations for the Conduct of Pilot Trials in Advanced Pancreas Cancer
Parameter | Recommendation |
---|---|
Patient selection | Restrict studies to patients with Eastern Cooperative Oncology Group performance status 0-1 |
Study patients with localized unresectable disease separately from those with metastatic disease | |
Establish uniform eligibility criteria | |
Use of predictive biomarkers for enrichment | |
Agents to be tested | Maximize input from preclinical data |
Adopt multitargeted approaches based on scientific rationale | |
Consider non–gemcitabine-based combinations | |
Statistical designs | Survival preferred primary end point |
Single arm and multiarm randomized studies each have their place | |
Correlative science | Incorporate hypothesis-driven correlative research in pilot trials |
Report negative as well as positive study outcomes | |
Consider prospective patient selection in pilot study setting based on data relating outcome with a specific molecular profile | |
Transition to phase III | Consider input from multiple studies |
Implement phase III testing only after a robust signal from pilot study(s) |